These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15938591)

  • 41. [Grounds and perspectives of using geviskon--novel in Russia alginate-containing drug--in treatment of acid-dependent diseases of the digestive system].
    Tkachenko EI; Uspenskiĭ IuP
    Eksp Klin Gastroenterol; 2007; (4):41-6. PubMed ID: 18409489
    [No Abstract]   [Full Text] [Related]  

  • 42. Characterization of raft-forming alginate suspensions formed in HCl or model food systems at varying pH levels to better simulate gastric postprandial conditions.
    Keppler S; Mannara G; Marra F; Bornhorst GM
    Drug Dev Ind Pharm; 2021 Jul; 47(7):1079-1089. PubMed ID: 34254865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment].
    Maestri L
    Pediatr Med Chir; 2001; 23(3-4):187-9. PubMed ID: 11723856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of 111In-labeled alginate to study the pH dependence of alginic acid anti-esophageal reflux barrier.
    Knight LC; Maurer AH; Ammar IA; Siegel JA; Fisher RS; Malmud LS
    Int J Rad Appl Instrum B; 1988; 15(5):563-71. PubMed ID: 3254879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
    Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
    Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
    Corvaglia L; Spizzichino M; Zama D; Aceti A; Mariani E; Legnani E; Faldella G
    Early Hum Dev; 2011 Dec; 87(12):775-8. PubMed ID: 21696897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastric pH and endoscopic appearance after Algicon administration.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():25-8; discussion 35-6. PubMed ID: 2511920
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and safety of sodium alginate for GERD in preterm infants.
    Erdeve O; Atasay B; Arsan S; Türmen T
    Aliment Pharmacol Ther; 2011 Apr; 33(8):981-2; author reply 982-3. PubMed ID: 21434951
    [No Abstract]   [Full Text] [Related]  

  • 49. Raft-forming agents: antireflux formulations.
    Kapadia CJ; Mane VB
    Drug Dev Ind Pharm; 2007 Dec; 33(12):1350-61. PubMed ID: 18097809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formulation, optimization, and evaluation of raft-forming formulations containing Nizatidine.
    Darwish MKM; Abu El-Enin ASM; Mohammed KHA
    Drug Dev Ind Pharm; 2019 Apr; 45(4):651-663. PubMed ID: 30638411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The alginate raft: a scintigraphic evaluation.
    McKay AP; Wraight EP; Hunter JO
    Br J Clin Pract Suppl; 1989 Feb; 66():20-4; discussion 35-6. PubMed ID: 2511919
    [No Abstract]   [Full Text] [Related]  

  • 52. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.
    Giannini EG; Zentilin P; Dulbecco P; Iiritano E; Bilardi C; Savarino E; Mansi C; Savarino V
    Dig Dis Sci; 2006 Nov; 51(11):1904-9. PubMed ID: 16977507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy.
    Lindow SW; Regnéll P; Sykes J; Little S
    Int J Clin Pract; 2003 Apr; 57(3):175-9. PubMed ID: 12723718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of sodium alginate on acid gastroesophageal reflux disease in preterm infants: a pilot study.
    Atasay B; Erdeve O; Arsan S; Türmen T
    J Clin Pharmacol; 2010 Nov; 50(11):1267-72. PubMed ID: 20489030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Using gaviscon preparation for relief of esophageal, extraesophageal syndromes and functional dyspepsia in elderly patients with GERD].
    Onuchina EV; Brikova SI; Tsukanov VV
    Eksp Klin Gastroenterol; 2010; (10):80-6. PubMed ID: 21434379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the efficacy and safety of a new aluminium-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux.
    Miller S
    Curr Med Res Opin; 1999; 15(3):160-8. PubMed ID: 10621922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Swelling, erosion and release behavior of alginate-based matrix tablets.
    Sriamornsak P; Thirawong N; Korkerd K
    Eur J Pharm Biopharm; 2007 Jun; 66(3):435-50. PubMed ID: 17267187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers.
    Tadros MI
    Eur J Pharm Biopharm; 2010 Feb; 74(2):332-9. PubMed ID: 19932750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alginate beads as a carrier for omeprazole/SBA-15 inclusion compound: A step towards the development of personalized paediatric dosage forms.
    Del Gaudio P; De Cicco F; Sansone F; Aquino RP; Adami R; Ricci M; Giovagnoli S
    Carbohydr Polym; 2015 Nov; 133():464-72. PubMed ID: 26344303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design of pH-responsive alginate raft formulation of risedronate for reduced esophageal irritation.
    Jang SW; Lee JW; Ryu DS; Son M; Kang MJ
    Int J Biol Macromol; 2014 Sep; 70():174-8. PubMed ID: 24995633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.